HEALTHY LIVING
06/06/2013 03:29 pm ET Updated Aug 06, 2013

Narrowly-Divided FDA Panel Votes To Modify Avandia Restrictions

Getty

WASHINGTON, June 6 (Reuters) - A narrowly divided U.S. Food and Drug Administration panel of outside experts on Thursday voted to modify market restrictions on GlaxoSmithKline's diabetes drug Avandia, the one-time blockbuster at the center of one of the biggest drug controversies in recent years.

Thirteen members of the advisory panel favored modification, while seven others voted to remove the restrictions altogether and five panel members favored keeping current safeguards in place without changes. One committee member voted to withdraw Avandia from the market altogether.

RELATED ON HUFFPOST:

PHOTO GALLERIES
What Affects Diabetes Risk?
Subscribe to the Lifestyle email.
Life hacks and juicy stories to get you through the week.